BRPI0717651A2 - Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1 - Google Patents

Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1

Info

Publication number
BRPI0717651A2
BRPI0717651A2 BRPI0717651-1A2A BRPI0717651A BRPI0717651A2 BR PI0717651 A2 BRPI0717651 A2 BR PI0717651A2 BR PI0717651 A BRPI0717651 A BR PI0717651A BR PI0717651 A2 BRPI0717651 A2 BR PI0717651A2
Authority
BR
Brazil
Prior art keywords
cancer vaccines
vaccines expressing
peptide cancer
expressing mphosph1
depdc1
Prior art date
Application number
BRPI0717651-1A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Tomoaki Fujioka
Yusuke Nakamura
Takuya Tsunoda
Ryuji Osawa
Midori Shida
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0717651A2 publication Critical patent/BRPI0717651A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
BRPI0717651-1A2A 2006-10-17 2007-10-16 Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1 BRPI0717651A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85257506P 2006-10-17 2006-10-17
PCT/JP2007/001122 WO2008047473A1 (en) 2006-10-17 2007-10-16 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides

Publications (1)

Publication Number Publication Date
BRPI0717651A2 true BRPI0717651A2 (pt) 2013-12-24

Family

ID=39313729

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717651-1A2A BRPI0717651A2 (pt) 2006-10-17 2007-10-16 Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1

Country Status (17)

Country Link
US (5) US8557955B2 (enExample)
EP (7) EP2687540A1 (enExample)
JP (2) JP5339292B2 (enExample)
KR (4) KR101527473B1 (enExample)
CN (5) CN101568550B (enExample)
AU (1) AU2007311395B2 (enExample)
BR (1) BRPI0717651A2 (enExample)
CA (2) CA2915560A1 (enExample)
DK (1) DK2091965T3 (enExample)
ES (4) ES2545457T3 (enExample)
IL (4) IL198186A (enExample)
MX (1) MX2009004147A (enExample)
PL (1) PL2091965T3 (enExample)
PT (1) PT2091965E (enExample)
RU (1) RU2469044C2 (enExample)
SG (2) SG10201502098YA (enExample)
WO (1) WO2008047473A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
US8455444B2 (en) * 2007-08-20 2013-06-04 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
EP2362904B1 (en) * 2008-08-28 2016-11-16 Oncotherapy Science, Inc. Method of screening compounds for use in inhibiting depdc1 - znf224 binding
WO2010100878A1 (en) * 2009-03-04 2010-09-10 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
WO2012032763A1 (en) * 2010-09-07 2012-03-15 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
KR102015648B1 (ko) * 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신
JP2013058294A (ja) * 2011-09-09 2013-03-28 Toshiba Corp 磁気記録媒体及び磁気記録媒体の製造方法
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
JP6041297B2 (ja) * 2012-08-24 2016-12-07 国立大学法人山口大学 犬リンパ腫の診断方法及び診断キット
CA2904802C (en) * 2013-03-13 2021-03-30 Zhong Li Microvesicle and method for producing the same
LT3132247T (lt) 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
JP6898225B2 (ja) 2015-03-09 2021-07-07 サイトリミック株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3797794A1 (en) 2015-04-07 2021-03-31 Cytlimic Inc. Medicine comprising a toll like receptor 3 agonist and a lag-3 protein
AU2016306527B2 (en) * 2015-08-12 2022-03-17 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
HK1251928A1 (en) * 2015-10-08 2019-05-03 Oncotherapy Science, Inc. MPHOSPH1-derived peptides and vaccines including it
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
WO2018092755A1 (en) * 2016-11-18 2018-05-24 Oncotherapy Science, Inc. Mphosph1 epitope peptides for th1 cells and vaccines containing the same
JP2019535270A (ja) * 2016-11-18 2019-12-12 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のためのＤＥＰＤＣ１エピトープペプチドおよびこれを含有するワクチン
WO2018094569A1 (zh) * 2016-11-22 2018-05-31 深圳华大基因研究院 多肽及其应用
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
SG11202000250PA (en) * 2017-07-12 2020-02-27 Nouscom Ag A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
RU2760984C1 (ru) 2017-12-13 2021-12-02 Иновио Фармасьютикалз, Инк. Противораковые вакцины, направленные на lemd1, и их применение
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
CN112142824B (zh) * 2019-06-27 2022-03-11 深圳市东贵博康生化科技有限公司 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体
CN116368570A (zh) * 2020-10-15 2023-06-30 米尼奥公司 用于确定肽免疫原性的方法、系统和计算机程序产品

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
RU94038427A (ru) 1991-08-26 1996-10-20 Сайтел Корпорейшн (US) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
JP3738395B2 (ja) 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
AU678225B2 (en) * 1993-03-11 1997-05-22 University Of Southern California Therapeutic strategies for immunoinfective cluster virus infections
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
JP2003518364A (ja) * 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
CA2420543C (en) 2000-08-22 2013-04-02 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
AU2001296235A1 (en) 2000-10-12 2002-04-22 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2425648A1 (en) * 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1356048A2 (en) * 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005515779A (ja) * 2002-01-31 2005-06-02 ワイス アグレカナーゼ分子
AU2003222103A1 (en) 2002-03-28 2003-10-13 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP5109131B2 (ja) * 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
JP2006302684A (ja) 2005-04-21 2006-11-02 D D K Ltd カードコネクタ
EP2295570A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
TWM336439U (en) * 2008-02-14 2008-07-11 Optivision Technology Inc Diffuser capable of light condensing
EP2362904B1 (en) * 2008-08-28 2016-11-16 Oncotherapy Science, Inc. Method of screening compounds for use in inhibiting depdc1 - znf224 binding
KR102015648B1 (ko) 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신

Also Published As

Publication number Publication date
AU2007311395A1 (en) 2008-04-24
CN101568550B (zh) 2012-12-26
KR101493773B1 (ko) 2015-03-03
HK1171024A1 (en) 2013-03-15
KR101527473B1 (ko) 2015-06-17
US20130129759A1 (en) 2013-05-23
KR20090083378A (ko) 2009-08-03
EP2687541A1 (en) 2014-01-22
EP2476699A3 (en) 2013-11-27
EP2476699A2 (en) 2012-07-18
IL198186A0 (en) 2011-08-01
SG175566A1 (en) 2011-11-28
EP2687540A1 (en) 2014-01-22
CN102850434B (zh) 2016-04-13
JP2010506826A (ja) 2010-03-04
US8653234B2 (en) 2014-02-18
ES2545457T3 (es) 2015-09-11
KR20140057681A (ko) 2014-05-13
IL198186A (en) 2017-05-29
EP2476697A3 (en) 2013-11-27
US8557955B2 (en) 2013-10-15
EP2695895A1 (en) 2014-02-12
CA2915560A1 (en) 2008-04-24
SG10201502098YA (en) 2015-05-28
CN102850434A (zh) 2013-01-02
US20120282286A1 (en) 2012-11-08
IL216712A0 (en) 2012-01-31
ES2545818T3 (es) 2015-09-16
US20100028373A1 (en) 2010-02-04
CA2667030C (en) 2016-03-15
EP2091965A4 (en) 2011-02-16
KR101454287B1 (ko) 2014-11-04
EP2476697B1 (en) 2015-06-17
EP2476698B1 (en) 2015-06-17
CN102850433B (zh) 2016-03-02
US20120288514A1 (en) 2012-11-15
AU2007311395B2 (en) 2013-02-21
WO2008047473A1 (en) 2008-04-24
CA2667030A1 (en) 2008-04-24
EP2476697A2 (en) 2012-07-18
JP2013116115A (ja) 2013-06-13
CN102850435B (zh) 2016-02-17
EP2091965A1 (en) 2009-08-26
EP2091965B9 (en) 2013-09-25
CN101568550A (zh) 2009-10-28
EP2476698A3 (en) 2013-11-27
ES2415958T3 (es) 2013-07-29
EP2476699B1 (en) 2015-06-17
US9017688B2 (en) 2015-04-28
KR20140104057A (ko) 2014-08-27
RU2469044C2 (ru) 2012-12-10
US9545437B2 (en) 2017-01-17
US20150231222A1 (en) 2015-08-20
CN105693843A (zh) 2016-06-22
IL216713A0 (en) 2012-01-31
KR101543622B1 (ko) 2015-08-11
IL216712A (en) 2017-07-31
PL2091965T3 (pl) 2013-10-31
DK2091965T3 (da) 2013-08-05
EP2476698A2 (en) 2012-07-18
KR20150015042A (ko) 2015-02-09
HK1131169A1 (en) 2010-01-15
RU2009118432A (ru) 2010-11-27
JP5339292B2 (ja) 2013-11-13
HK1171026A1 (en) 2013-03-15
CN102850433A (zh) 2013-01-02
US8552146B2 (en) 2013-10-08
IL222925A0 (en) 2012-12-31
CN102850435A (zh) 2013-01-02
ES2545817T3 (es) 2015-09-16
MX2009004147A (es) 2009-06-15
HK1171025A1 (en) 2013-03-15
PT2091965E (pt) 2013-06-11
EP2091965B1 (en) 2013-05-15

Similar Documents

Publication Publication Date Title
PL2091965T3 (pl) Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
DK2035447T3 (da) Polypeptid
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
DK3118220T3 (da) Protein
IL221062B (en) Stitched polypeptides
EP2093287A4 (en) PEPTIDE BINDER IGG
EP2215246A4 (en) PROTEIN SCAFFOLDS
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
DK2046826T3 (da) Exendin-fusionsproteiner
EP2212691A4 (en) MICROCHIP
EP2278994A4 (en) Flagellin POLYPEPTIDE VACCINES
DK2139987T3 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
LTPA2018508I1 (lt) Anti-FGF23 antikūnas ir jį apimanti farmacinė kompozicija
BRPI0814971A2 (pt) Proteína
PT2186889E (pt) Péptido cdca1 e agente farmacêutico que o compreende
BRPI0812489A2 (pt) Genes que codificam proteínas inseticidas
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
EP2300033A4 (en) CONJUGATES OF COLLAGEN PEPTIDE AND USES THEREOF
EP1835927A4 (en) MODIFIED BETATHYMOSINE PEPTIDES
IL202059A0 (en) Identification of oxidatively modified peptide sequences in the proteome
BRPI0721348A2 (pt) Capa para calças e calçados
ATE556106T1 (de) Lederwerkstoff
DK2069093T3 (da) Nedholder til pladesakse
BRPI0815379A2 (pt) peptídeos modificados tendo efeitos intesificadores de toxina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.